Hutchmed Says China Grants Priority Review for Sovleplenib in Autoimmune Hemolytic Anemia
MT Newswires Live
Apr 29
Hutchmed (HCM) said Wednesday that China's National Medical Products Administration accepted the new drug application and granted priority review for sovleplenib to potentially treat warm antibody autoimmune hemolytic anemia.
The company said its application was supported by data from a phase 2/3 study in China. In January, the phase 3 part of the trial met its primary endpoint of durable hemoglobin response rate within weeks 5 to 24 of treatment, the company added.
The Chinese regulator also granted breakthrough therapy designation for sovleplenib in warm antibody autoimmune hemolytic anemia in March, Hutchmed said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.